{
    "title": "Foamix's acne drug misses main goal in key study, shares slump",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4352980/Foamixs-acne-drug-misses-main-goal-late-stage-study.html",
    "date": "2017-03-27",
    "keywords": [
        "drug",
        "latestage",
        "grover",
        "acne",
        "divya",
        "monday",
        "treatment",
        "study",
        "fmx101",
        "reduction",
        "xenon",
        "percent",
        "grovermarch",
        "developer",
        "saidfmx101",
        "version",
        "minocycline",
        "form",
        "side",
        "effectsthe",
        "total",
        "placebo",
        "trial",
        "assessment",
        "severity",
        "lesion",
        "count",
        "goal",
        "relation",
        "scale",
        "studyfoamix",
        "phase",
        "saidfoamix",
        "data",
        "food",
        "administration",
        "company",
        "saidit",
        "path",
        "fda",
        "remainder",
        "sufficient",
        "filing",
        "approval",
        "readthrough",
        "fmx103",
        "plc",
        "novan",
        "inc",
        "week",
        "midstage",
        "allergan",
        "paratek",
        "studiesfoamix",
        "skin",
        "rosacea",
        "impetigo",
        "rashesacne",
        "condition",
        "academy",
        "stock",
        "bengaluru",
        "editing",
        "sai",
        "ravikumar",
        "shounak",
        "dasgupta"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}